peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Anna Runström, Hansa Biopharma

Working in an epicentre of pioneering innovation

The story of Anna: the eighth employee at Hansa Biopharma

"The key to our collective success at Hansa Biopharma goes far beyond our scientific breakthroughs, as it stems from the amazing team spirit we have built. Every day we inspire each other, and that drives us in our daily work.”

Moving to Hansa from Active Biotech alongside founder and former owner of Hansa, Bo Håkansson, Anna was only the eighth employee to join in 2012. Since then, the number of employees has grown to over 150 worldwide. She has been at the forefront of the company’s research and development program ever since.

“I have had a fantastic opportunity to grow within my role as a scientist. The company believed in me and entrusted me with increasing responsibility.”

When she first joined Hansa, Anna’s role involved a broad spectrum of research including in vivo, in vitro, and clinical research into Hansa’s unique IgG-cleaving enzyme technology to understand and harness its ability. Lately, Anna’s focus has been on advancing this technology for use in kidney transplantation, and her area of expertise specifically lies in working with the Luminex platform used for the evaluation of donor-specific antibodies in kidney patients. Due to the growth of preclinical research and clinical trial portfolios, Hansa’s workforce has grown quickly, and become increasingly ‘hands on’ due to its ever-expanding laboratory work and growing clinical trials program.

Anna is confident about Hansa’s future both because of the ongoing and expected launches of its first product in the area of kidney transplantation, and the next generation of IgG-cleaving enzyme technology in the pipeline.

“I hope and believe that Hansa’s therapies can be lifesaving in the fields of transplantation and autoimmunity”.